FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897940123> ?p ?o ?g. }

• W2897940123 abstract "Objectives 1) To evaluate the role of inflammatory mediators and adipokines in the cardiovascular risk profile and the metabolic comorbidities associated with psoriatic arthritis (PsA). 2) To evaluate the effect of apremilast in the adipocytokine pattern, metabolic components and endothelial dysfunction in patients with PsA and metabolic syndrome (MetSyn). Methods 55 PsA patients and 30 age and gender-matched healthy donors (HD) were analysed. An extensive clinical analysis including body index mass, lipid profile, HOMA-IR and intra-arterial blood pressure was performed. Endothelial function was measured through post occlusive hyperemia using Laser-Doppler. Different proinflammatory cytokines (TNFa, IL1b and IL6), vascular adhesion molecules (VEGF and E-Selectin) and adipokines (adiponectin, leptin, resistin and visfatin) were analysed on serum by ELISA. Ten biological-naive patients with PsA having metabolic syndrome were given apremilast 30 mg twice daily for 6 months. All the measures were carried out at basal, week 4 and week 24 after apremilast treatment. Results The prevalence of metabolic comorbidities such as MetSyn, obesity and insulin resistance (IR) was significant higher in PsA compared to HD. PsA patients had impaired endothelial function showed by a reduced peak flow and hyperaemia area and increased levels of VEGF and E-Selectin in serum. The levels of adipocytokines were significantly higher in PsA compared to HD. The body mass index values were significantly correlated with the clinical inflammatory parameters (CRP and ESR) and activity of the disease (swollen joints count and DAS28). Increased levels of HOMA-IR also correlated with DAS28, clinical and serological inflammatory markers, and diverse adipokines. Elevated levels of cytokines correlated with the activity of the disease and lipid alterations. Significant improvements in efficacy outcomes, including DAS-28 using erythrocyte sedimentation rate (ESR), tender and swollen joint count, Visual Analogue Scale (VAS), enthesitis and morning stiffness severity, were observed with apremilast at week 4. No changes on BMI were noticed. A significant reduction of intra-arterial blood pressure was evidenced since the first 4 weeks. Serum levels of Apolipoprotein A and B, insulin and HOMA-IR values were also significantly reduced after 24 weeks of treatment. Endothelial dysfunction was significantly restored shown by an increase of the peak flow and hyperaemia area and decreased adhesion molecules in serum. Levels of interleukins and adipokines were also modulated after apremilast treatment. Conclusions PsA is associated with an increase in inflammatory cytokines and adipokines, alongside with an endothelial dysfunction. These alterations are related to the disease activity and the presence of metabolic comorbidities such as insulin resistance or obesity, contributing to the burden of cardiovascular disease risk. Apremilast might reduce IR, inflammation, hypertension, lipids and endothelial dysfunction, parameters strongly involved in cardiovascular disease. Acknowledgements Supported by the Minister of Health (ISCIII, PI17/01316, RIER RD16/0012/0015) cofinanced with FEDER funds. Disclosure of Interest None declared" @default.
• W2897940123 created "2018-10-26" @default.
• W2897940123 creator A5015773018 @default.
• W2897940123 creator A5022821328 @default.
• W2897940123 creator A5049175756 @default.
• W2897940123 creator A5052676135 @default.
• W2897940123 creator A5068086541 @default.
• W2897940123 creator A5069183377 @default.
• W2897940123 creator A5071420318 @default.
• W2897940123 creator A5072074958 @default.
• W2897940123 creator A5078135216 @default.
• W2897940123 creator A5082544878 @default.
• W2897940123 date "2018-06-01" @default.
• W2897940123 modified "2023-10-18" @default.
• W2897940123 title "SAT0331 Inflammatory markers and adipokines related to cardiovascular risk and metabolic comorbidities in psoriatic arthritis. in vivo effects of apremilast" @default.
• W2897940123 doi "https://doi.org/10.1136/annrheumdis-2018-eular.6259" @default.
• W2897940123 hasPublicationYear "2018" @default.
• W2897940123 type Work @default.
• W2897940123 sameAs 2897940123 @default.
• W2897940123 citedByCount "0" @default.
• W2897940123 crossrefType "proceedings-article" @default.
• W2897940123 hasAuthorship W2897940123A5015773018 @default.
• W2897940123 hasAuthorship W2897940123A5022821328 @default.
• W2897940123 hasAuthorship W2897940123A5049175756 @default.
• W2897940123 hasAuthorship W2897940123A5052676135 @default.
• W2897940123 hasAuthorship W2897940123A5068086541 @default.
• W2897940123 hasAuthorship W2897940123A5069183377 @default.
• W2897940123 hasAuthorship W2897940123A5071420318 @default.
• W2897940123 hasAuthorship W2897940123A5072074958 @default.
• W2897940123 hasAuthorship W2897940123A5078135216 @default.
• W2897940123 hasAuthorship W2897940123A5082544878 @default.
• W2897940123 hasBestOaLocation W28979401231 @default.
• W2897940123 hasConcept C126322002 @default.
• W2897940123 hasConcept C134018914 @default.
• W2897940123 hasConcept C164027704 @default.
• W2897940123 hasConcept C194832188 @default.
• W2897940123 hasConcept C2776260265 @default.
• W2897940123 hasConcept C2776782570 @default.
• W2897940123 hasConcept C2776914184 @default.
• W2897940123 hasConcept C2777077863 @default.
• W2897940123 hasConcept C2777391703 @default.
• W2897940123 hasConcept C2779760629 @default.
• W2897940123 hasConcept C2780578515 @default.
• W2897940123 hasConcept C2780972559 @default.
• W2897940123 hasConcept C511355011 @default.
• W2897940123 hasConcept C71924100 @default.
• W2897940123 hasConceptScore W2897940123C126322002 @default.
• W2897940123 hasConceptScore W2897940123C134018914 @default.
• W2897940123 hasConceptScore W2897940123C164027704 @default.
• W2897940123 hasConceptScore W2897940123C194832188 @default.
• W2897940123 hasConceptScore W2897940123C2776260265 @default.
• W2897940123 hasConceptScore W2897940123C2776782570 @default.
• W2897940123 hasConceptScore W2897940123C2776914184 @default.
• W2897940123 hasConceptScore W2897940123C2777077863 @default.
• W2897940123 hasConceptScore W2897940123C2777391703 @default.
• W2897940123 hasConceptScore W2897940123C2779760629 @default.
• W2897940123 hasConceptScore W2897940123C2780578515 @default.
• W2897940123 hasConceptScore W2897940123C2780972559 @default.
• W2897940123 hasConceptScore W2897940123C511355011 @default.
• W2897940123 hasConceptScore W2897940123C71924100 @default.
• W2897940123 hasLocation W28979401231 @default.
• W2897940123 hasOpenAccess W2897940123 @default.
• W2897940123 hasPrimaryLocation W28979401231 @default.
• W2897940123 hasRelatedWork W1509424135 @default.
• W2897940123 hasRelatedWork W1607837250 @default.
• W2897940123 hasRelatedWork W1915500634 @default.
• W2897940123 hasRelatedWork W201734296 @default.
• W2897940123 hasRelatedWork W2039753946 @default.
• W2897940123 hasRelatedWork W2119207396 @default.
• W2897940123 hasRelatedWork W2168256748 @default.
• W2897940123 hasRelatedWork W2171507418 @default.
• W2897940123 hasRelatedWork W2334678473 @default.
• W2897940123 hasRelatedWork W2410551207 @default.
• W2897940123 hasRelatedWork W2410998261 @default.
• W2897940123 hasRelatedWork W2550385697 @default.
• W2897940123 hasRelatedWork W2550545444 @default.
• W2897940123 hasRelatedWork W2951284701 @default.
• W2897940123 hasRelatedWork W2951579579 @default.
• W2897940123 hasRelatedWork W2984887699 @default.
• W2897940123 hasRelatedWork W3000544679 @default.
• W2897940123 hasRelatedWork W3021082271 @default.
• W2897940123 hasRelatedWork W3022607022 @default.
• W2897940123 hasRelatedWork W3091880726 @default.
• W2897940123 isParatext "false" @default.
• W2897940123 isRetracted "false" @default.
• W2897940123 magId "2897940123" @default.
• W2897940123 workType "article" @default.